BR100 Increased By (0.01%)
BR30 Increased By (0.53%)
KSE100 Increased By (0.28%)
KSE30 Increased By (0.29%)
AGHA 6.35 Increased By ▲ 0.03 (0.47%)
BECO 4.39 Increased By ▲ 0.12 (2.81%)
BML 62.50 Increased By ▲ 0.05 (0.08%)
BOP 31.47 Increased By ▲ 0.24 (0.77%)
CNERGY 11.70 Increased By ▲ 0.11 (0.95%)
CSIL 5.92 Increased By ▲ 0.20 (3.5%)
FCCL 61.60 Increased By ▲ 0.06 (0.1%)
FFL 14.79 Decreased By ▼ -0.23 (-1.53%)
FNEL 1.23 No Change ▼ 0.00 (0%)
KEL 6.33 Increased By ▲ 0.07 (1.12%)
KOSM 5.90 Increased By ▲ 0.34 (6.12%)
LOTCHEM 24.79 Increased By ▲ 0.11 (0.45%)
MLCF 103.93 Decreased By ▼ -0.15 (-0.14%)
NBP 173.05 Decreased By ▼ -2.23 (-1.27%)
NCPL 51.85 Decreased By ▼ -0.92 (-1.74%)
NPL 54.19 Increased By ▲ 0.07 (0.13%)
OGDC 315.50 Increased By ▲ 2.11 (0.67%)
PACE 9.26 Increased By ▲ 0.06 (0.65%)
PAEL 35.51 Decreased By ▼ -0.29 (-0.81%)
PIBTL 13.65 Increased By ▲ 0.18 (1.34%)
PPL 226.60 Increased By ▲ 4.79 (2.16%)
PRL 80.30 Increased By ▲ 1.22 (1.54%)
PTC 46.89 Increased By ▲ 0.04 (0.09%)
SSGC 23.90 Increased By ▲ 0.03 (0.13%)
TBL 9.30 Decreased By ▼ -0.01 (-0.11%)
TELE 7.65 Increased By ▲ 0.26 (3.52%)
TPL 24.51 Decreased By ▼ -0.60 (-2.39%)
TPLP 13.04 Increased By ▲ 0.53 (4.24%)
TREET 26.05 Decreased By ▼ -0.20 (-0.76%)
TRG 53.38 Decreased By ▼ -0.06 (-0.11%)
World Print edition: 2019-11-04

Medicinal cannabis not proven in mental health

Evidence is weak for whether medicinal cannabis treatments can relieve mental illnesses such as anxiety, depression and psychosis, and doctors should prescribe them with great caution, researchers said on Monday.
Published Updated

Evidence is weak for whether medicinal cannabis treatments can relieve mental illnesses such as anxiety, depression and psychosis, and doctors should prescribe them with great caution, researchers said on Monday.

In a review of scientific studies that analyzed the impact of medicinal cannabinoids on six mental health disorders, the researchers found "a lack of evidence for their effectiveness."

Their findings have important implications for countries such as the United States, Australia, Britain and Canada, where medical cannabis is being made available for patients with certain illness, said Louisa Degenhardt, a drug and alcohol expert at Australia's University of New South Wales in Sydney.

"There is a notable absence of high-quality evidence to properly assess the effectiveness and safety of medicinal cannabinoids and until evidence from randomized controlled trials is available, clinical guidelines cannot be drawn up around their use in mental health disorders," she said as her results were published in The Lancet Psychiatry journal.

Copyright Reuters, 2019

Comments

Comments are closed for this article.